Tag: ParaGard

ParaGard

Regulatory/FDA

Two Recent OPDP Letters Prompted by “Bad Ad Program” Complaints

Two Recent OPDP Letters Prompted by “Bad Ad Program” Complaints

March 15, 2021 – The FDA Office of Prescription Drug Promotion (OPDP) marked the 10-year anniversary of the Bad Ad Program in 2020, and kicks off 2021 with three enforcement actions – two Warning Letters and one Untitled Letter – two of which cited the Bad Ad Program as the source of complaints about potentially […]

Read more

Regulatory/FDA

Latest OPDP Enforcement Letters: Don’t Omit or Distract from Risk Information

Latest OPDP Enforcement Letters: Don’t Omit or Distract from Risk Information

Aug. 5, 2019 – In two new Untitled Letters, the FDA’s Office of Prescription Drug Promotion (OPDP) makes clear that omitting risk information, misrepresenting product efficacy and using visuals that distract from risk messaging in direct-to-consumer (DTC) broadcast ads may draw the agency’s enforcement attention. In a July 25 Untitled Letter to CooperSurgical Inc., OPDP […]

Read more